All News
Measuring Disease Activity in PsA: Dr. Eric Ruderman
In this video, Dr. Eric Ruderman looks at abstracts #0884, #0323 and #0909, which focus on disease activity measurement in psoriatic arthritis, presented at the 2020 ACR Convergence meeting earlier this month.
Read Article
The tantalising prospect of glucocorticoid-free treatments for systemic vasculitis
Glucocorticoids are a highly effective treatment in systemic vasculitis but are also a significant cause of long-term harm in the form of treatment related adverse events.
Read Article
Check on Pneumococcal Vaccination: Dr. Janet Pope ( @Janetbirdope) #ACR20
https://t.co/D9EQ3Tl2Ot https://t.co/Zn8IVorCcs
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @CreakyJoints : .@LCalabreseDO from @ClevelandClinic is discussing the science of #empathy in #rheumatology at #ACR20.
How important is empathy in your doctor-patient relationship? https://t.co/dnJ3f8QouE
Dr. John Cush RheumNow ( View Tweet)
Revisit our #ACR20 coverage. Listen to our Day 3 part II recap. Follow the link below or find us on Apple/Android podcasts.
https://t.co/1TcXfU5TMg https://t.co/hn298mJIUL
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @SattuiSEMD :L06: Mavrilimumab in #GCA
Efficacy+safety of MAV maintaining sustained remission 26w new and relapsing/ref #GCA
Flare risk ➡️ 62% risk ⬇️ of flare w/ MAV
Sustained remission➡️ 33% ⬆️ in MAV
No diff in new/relapsing/ref pts, No diff in AE
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
"RT @DrMiniDey : RITAZAREM trial long-term f/u
-RTX vs AZA after RTX-induced remission in ANCA
-RTX superior to AZA to prevent relapse
-Relapse common regardless of therapy; high-dose RTX not effective beyond treatment period
Abs#2052
https://t.co/cKV7qM77og
Links:
Dr. John Cush RheumNow ( View Tweet)
Fibromyalgia Therapies Show Limited Evidence of Pain and QOL Reduction
https://t.co/jpZC4KFygJ https://t.co/k7WFNQg9AY
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @ejdein1 : Dr. Khanna NOVESA study #ACR20 Abst#L09. Autotaxin inhibitor ZIRI in early dcSSc. 21 pts ziri vs 12 PBO. mRSS at Wk24 mean difference -2.8. Ziri well-tolerated. Would be great for new drug for early SSc skin. @RheumNow. https://t.co/TOS9fp4gGK https://t.co/4SDisedzs3
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Conway ( @RichardPAConway) and Dr. Maguire discuss abstract #1323 presented at the #ACR20 on pregnancy in Spondyloarthritis.
https://t.co/YyWOuiq3jn https://t.co/SnodUbKZTx
Links:
Dr. John Cush RheumNow ( View Tweet)
Timely video on COVID 19 and Rheumatic Disease with Dr. Jeffrey Sparks ( @jeffsparks) #acr20
https://t.co/5Qg3HRkQyW https://t.co/x0iQ6XX3eJ
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @MeralElRamahiMD : Wonder if you can predict development of clinical RA in those at risk either w/ a
- +RF or +CCP
- Relevant sxs w/ or w/o abs
- 1st deg relatives do RA pts?
#ACR20 https://t.co/xVZHxL35UY
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @RADoctor: Adjuvant #herpeszoster vaccine (Shingrix) not effective for 25% of JAKi-treated RA pts (n=40) for antibody response (T cell response usually worse, not reported). Is better than nothing good enough? Maybe we need to hold JAKi briefly?
Dr. John Cush RheumNow ( View Tweet)
New video! Risk of HCQ Retinopathy: Dr. Kathryn Dao ( @KDAO2011) #ACR20
https://t.co/7BCVvMOm0T https://t.co/DOW91SSi2u
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
"RT @drdavidliew : This - very cool.
Not as impressive as the implanted vagal stimulation pilot data, but once a day and well tolerated. Very early days but enticing, we will see!
#ACR20 ABST1995 @RheumNow https://t.co/cE3gQar0zo https://t.co/bmGnrMGaq3
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Janet Pope ( @Janetbirdope) reviews abstract #1001 presented at #ACR20 on risk of skin cancer with methotrexate.
https://t.co/N0JelI6K5p https://t.co/n07HoO5j3y
Links:
Dr. John Cush RheumNow ( View Tweet)
Revisit our #ACR20 coverage. Listen to our Day 3 recap. Follow the link below or find us on Apple/Android podcasts.
https://t.co/IbfY5vbBAo https://t.co/YL9fAuO0oz
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @DrPetryna : #ACR20 Abs L08 Prosp. 4 year PROBE trial of Febuxostat vs allopurinol long term CV safety: febuxostat not associated w/increased risk of death compared w/allopurinol.7.2% pts died in the febuxostat group compared to 8.6% in the allopurinol group
Dr. John Cush RheumNow ( View Tweet)
SpA: Etiology to Diagnosis to Treatment - An Abstract Roundup by Dr. Robert Chao ( @doctorRBC) #ACR20
https://t.co/wR0inoR8jp https://t.co/7SFkThkPSr
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @doctorRBC : Mavrilimumab efficacious in maintaining disease remission in GCA pts.
Phase 2 trial (n=70)
Disease flare 19% in tx vs. 46% in PBO at 26wk
Sustained remission 83% vs. 50% in PBO
Similar AE in both groups Abs#L06
https://t.co/fsZxZVmDIu" https://t.co/j17naatAxX
Links:
Dr. John Cush RheumNow ( View Tweet)